Drugs in Dev. Infections and Infectious Diseases
Phase II/ Phase III
France 
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)
Details : Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.
Product Name : Sarconeos
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound
Details : The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
Product Name : Sarconeos
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Acoziborole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : DNDi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Acoziborole, a potentially transformative investigational treatment for sleeping sickness, has a favourable safety profile, with no significant drug-related safety signals reported.
Product Name : SCYX-7158
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Acoziborole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : DNDi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19
Details : The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.
Product Name : Kevzara
Product Type : Antibody
Upfront Cash : Inapplicable
March 16, 2020
Lead Product(s) : Sarilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CER-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Bpifrance
Deal Size : $9.1 million
Deal Type : Funding
ABIONYX Pharma Receives €8.7M to Fight Sepsis from French Government
Details : The funding will be used for ABIONYX Pharma’s CER-001 Sepsis project. CER-001 is a negatively-charged lipoprotein particle which contains human recombinant apoA-I.
Product Name : CER-001
Product Type : Protein
Upfront Cash : Undisclosed
February 20, 2025
Lead Product(s) : CER-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Bpifrance
Deal Size : $9.1 million
Deal Type : Funding
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarconeos (BIO101) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating severe forms of COVID-19.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarconeos (20-hydroxyecdysone) activates the MAS receptor, a key component of the protective arm of the RAS, and has been shown to significantly improve respiratory function in several preclinical models. It is being developed for treating COVID-19.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.8 million
Deal Type : Public Offering
Biophytis Announces $3.8 Million Registered Direct Offering
Details : The proceeds will fund research and development and clinical trials of its product canditates including, Sarconeos (BIO101), a small molecule in development for age-related neuromuscular (sarcopenia and Duchenne muscular dystrophy) and cardiorespiratory ...
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $3.8 million
Deal Type : Public Offering
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Intsel Chimos
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sarconeos (BIO101, 20-hydroxyecdysone), is a small molecule, administered orally, a key component of the protective arm of the RAS, has shown positive results in the treatment of adult patients with a severe form of COVID-19.
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Intsel Chimos
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug BIO101 (sarconeos) developed by Biophytis, requested for the treatment of severe forms of COVID-19, if...
Product Name : BIO101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 03, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Agreement
Reset All
Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
